SCHEMBL1772863

SCHEMBL1772863

CC1(C)NC(=O)N(c2ccc(Oc3ccc(C(F)(F)F)cc3)cc2)C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 10/20 0.59
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
PGR P06401 1/20 0.49
CYP2D6 P10635 1/20 0.49
TSHR P16473 1/20 0.49
ALOX12 P18054 1/20 0.49
NFKB1 P19838 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
PDE4D Q08499 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 1/20 0.42
MMP1 P03956 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11480812 0.91 AR (0.68) ARCYP3A4CYP2C9CYP2C19LMNA
SCHEMBL1191959 0.82 AR (0.55) ARLMNATSHRSMN1; SMN2MMP2
SCHEMBL2940562 0.81 AR (0.55) ARCYP3A4CYP2C9CYP2C19LMNA
SCHEMBL1773418 0.81 AR (0.54) ARLMNASMN1; SMN2MMP1MMP2
SCHEMBL21953180 0.78 AR (0.46) ARCYP3A4CYP2C9CYP2C19LMNA
SCHEMBL1877843 0.77 AR (0.60) ARCYP3A4CYP2C9CYP2C19LMNA
SCHEMBL1978201 0.76 SMN1; SMN2 (0.51) ARLMNAMEN1TSHRRAB9A
SCHEMBL30939585 0.76 SMN1; SMN2 (0.51) ARLMNAMEN1TSHRRAB9A
SCHEMBL1982664 0.75 AR (0.47) ARCYP3A4CYP2C9CYP2C19LMNA
SCHEMBL30939596 0.75 AR (0.47) ARCYP3A4CYP2C9CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed
EP-2242747-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 EP disclosed
WO-2009097997-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC AR 2449/4885CYP3A4 75/4885CYP2C9 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.